The Mexican Social Security Institute has moved to seize property and equipment from the Eli Lilly, Baxter, Fresenius Kabi, Pisa, Probiomed and Cryopharma medical laboratories. The companies have been involved in a price-fixing scheme, costing the IMSS over $660 million pesos (US $ 37.4 million) in excess charges.
“Fortunately we have been able to seize assets from several of the companies. Obviously, this has nothing to do with a subjective issue, this is in litigation, and we are guaranteeing the patrimony of the IMSS because, as established by COFECE and the Supreme Court, it was an absolute monopolistic practice “said IMSS director Mikel Arreola.
In April 2015, the Supreme Court upheld COFECE’s resolution against the pharmaceutical companies for manipulating IMSS tenders in the purchase of insulin and serums, causing a rise of up to 57.6% in prices. Since the ruling, the IMSS expects pharmacists to make reparations. The seizures seek to ensure that the laboratories comply with payment of the fines.
Full Content: El Universal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Massachusetts AG Sues Insulin Makers and PBMs Over Alleged Price-Fixing Scheme
Jan 14, 2025 by
CPI
Apple and Amazon Avoid Mass Lawsuit in UK Over Alleged Collusion
Jan 14, 2025 by
CPI
Top Agent Network Drops Antitrust Suit Against National Association of Realtors
Jan 14, 2025 by
CPI
Weil, Gotshal & Manges Strengthens Antitrust Practice with New Partner
Jan 14, 2025 by
CPI
Russian Court Imposes Hefty Fine on Google for Non-Compliance with Content Removal Orders
Jan 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand